semaglutide centerville Peptide Therapy Clinics in Centerville, OH Diabetes Drug Could Help Reduce

For a small additional fee, we also invite you to receive your injections in our office each week

Individual results may vary based on health conditions and other factors.

A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52

Every patient is different, so results will vary

Right upper abdominal pain, fever, or yellowing of the skin/eyes , which may indicate gallbladder problems, as GLP-1 receptor agonists have been associated with an increased risk of gallstone formation